Drug intelligence / Profile preview

KCL-002

Development stage: Preclinical
Lead developer: Aethox Therapeutics
Modality: Small Molecules
Administration: Oral

Overview

KCL-002 is a preclinical-stage small molecule being developed by Aethox Therapeutics for the treatment of solid tumors. It is the primary component of the ATX201 development program, where it is intended to be administered in combination with an undisclosed chemotherapy agent. As of early 2024, the specific molecular target and mechanism of action for KCL-002 have not been publicly disclosed by the developer, though the company's broader platform focuses on modulating the tumor microenvironment to enhance the efficacy of standard-of-care treatments and overcome chemotherapy resistance.

Targets

HMOX1 (Heme oxygenase 1)

Beyond the preview

Go deeper on KCL-002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KCL-002.

Explore the full profile